In a first, AI-powered breast cancer chemotherapy test wins FDA approval

WASHINGTON: In a major breakthrough for precision oncology and artificial intelligence-driven healthcare, the U.S. Food and Drug Administration (FDA) has cleared the first AI-powered digital pathology tool designed to help guide chemotherapy decisions for certain breast cancer patients.

The approved technology, called ArteraAI Breast, is designed to predict the likelihood of cancer metastasis and recurrence in patients with early-stage hormone receptor-positive (HR+), HER2-negative invasive breast cancer — one of the most common forms of breast cancer worldwide.

Healthcare experts say the approval could mark a significant shift toward more personalized cancer treatment strategies, helping physicians identify which patients may benefit from chemotherapy and which may safely avoid the toxic side effects associated with aggressive treatment.

AI tool aims to personalize breast cancer treatment

According to Artera, the AI-driven platform analyzes digitized pathology slides from breast cancer tissue samples alongside clinical data to estimate a patient’s risk of distant metastasis.

The multimodal artificial intelligence model was trained using clinical trial data from more than 8,500 breast cancer patients.

Using this information, the system classifies patients into low-risk or high-risk groups based on their likelihood of cancer recurrence or spread.

Experts say this could help oncologists make more informed treatment decisions while reducing overtreatment in patients with lower-risk disease.

“Patients and clinicians need to understand their risks for recurrence and decide which treatments will be the most effective, thereby avoiding both undertreatment and overtreatment,” said Dr. Calvin Chao, vice president of medical science at Artera.

Related story: Liquid biopsy may predict breast cancer therapy response faster

Why the FDA approval matters

Breast cancer remains one of the world’s most significant health challenges.

According to global estimates from 2022, approximately 2.3 million women were diagnosed with breast cancer worldwide, while around 670,000 deaths were linked to the disease.

Although survival rates have improved due to advances in screening and treatment, oncologists say determining the right intensity of therapy remains one of the biggest challenges in breast cancer care.

Currently, many treatment decisions rely on genomic tests such as Oncotype DX, which can estimate recurrence risk and determine whether chemotherapy may provide additional benefit.

However, experts note that these tests can be expensive, may require several weeks for processing and are not always immediately accessible.

Related story: Quick, pain-free breast cancer imaging: OneTouch-PAT identifies tumors in under a minute

Experts say AI may reduce delays and unnecessary chemotherapy

Medical specialists believe the newly approved AI model could potentially shorten waiting times and simplify treatment planning by using already available pathology images and clinical information.

Dr. Richard Reitherman, a board-certified radiologist and medical director of breast imaging at MemorialCare Breast Center in California, described the technology as a potentially important advancement in oncology decision-making.

“The potential breakthrough in the multimodal artificial intelligence model is that it uses immediately available clinical and histopathologic features to assign patients into low and high-risk metastasis groups without the costs and time delays associated with current methods,” he explained.

Healthcare experts say this approach may help doctors make earlier treatment decisions, particularly in situations where chemotherapy decisions are unclear.

Potential to spare patients from chemotherapy side effects

Oncology experts say one of the biggest benefits of AI-assisted risk prediction may be the ability to reduce unnecessary chemotherapy exposure in lower-risk patients.

Chemotherapy can cause serious physical and emotional side effects including:
• Fatigue
• Neuropathy
• Increased infection risk
• Fertility complications
• Nausea and vomiting
• Long-term cardiovascular effects

Dr. Donna McNamara, a breast medical oncologist at Hackensack University Medical Center in New Jersey, described the FDA clearance as a major milestone in personalized cancer care.

“The potential to spare low-risk patients from the significant toxicities of chemotherapy is a major advantage. If we can safely identify patients who will not derive significant benefit from treatment, we can reduce unnecessary physical, emotional and financial burdens,” she said.

Despite the excitement surrounding the technology, cancer specialists stress that long-term clinical validation remains essential before widespread adoption.

Experts say AI-based tools must demonstrate consistent accuracy across diverse patient populations and show outcomes comparable to existing gold-standard testing methods.

Some oncologists have emphasized the importance of understanding how AI models generate risk assessments before relying heavily on them for treatment decisions.

AI rapidly expanding in cancer diagnostics

The FDA clearance reflects the growing role of artificial intelligence in modern medicine, particularly in radiology, pathology and oncology.

Healthcare analysts say AI-driven diagnostics are increasingly being developed to improve disease prediction, personalize treatments and optimize clinical workflows.

Experts believe future AI applications may further transform cancer screening, prognosis assessment and treatment planning, potentially improving survival outcomes while reducing unnecessary medical interventions.

For breast cancer patients, specialists say the emergence of AI-guided treatment tools could represent an important step toward more precise, individualized and less invasive care.

Stay informed, stay alert

CLICK HERE TO JOIN Medical News Pakistan on WhatsApp for real-time health alerts, expert insights, and breakthrough medical discoveries.